BIOGEN INC. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
BIOGEN INC. (BIIB) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $600.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-06.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2019-02-06
- BIOGEN INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2016 was $600.00K, a 99.13% decline from fiscal 2015.
- BIOGEN INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $69.00M, a 25.81% decline from fiscal 2014.
- BIOGEN INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2014 was $93.00M, a 102.61% increase from fiscal 2013.
- BIOGEN INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2013 was $45.90M, a 7.06% decline from fiscal 2012.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month as first filed |
|---|---|---|
| 2016-12-31 | $600.00K 10-K · filed 2019-02-06 | |
| 2015-12-31 | $69.00M 10-K · filed 2018-02-01 | |
| 2014-12-31 | $93.00M 10-K · filed 2017-02-02 | $92.97M 10-K · filed 2015-02-04 |
| 2013-12-31 | $45.90M 10-K · filed 2016-02-03 | $45.89M 10-K · filed 2014-02-06 |
| 2012-12-31 | $49.39M 10-K · filed 2015-02-04 | |
| 2011-12-31 | $50.38M 10-K · filed 2014-02-06 | |
| 2010-12-31 | $19.31M 10-K · filed 2013-02-05 | |
| 2009-12-31 | -$36.83M 10-K · filed 2012-02-03 | |
| 2008-12-31 | $29.84M 10-K · filed 2011-02-04 | |
| 2007-12-31 | $67.23M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |